CSPC Pharma Begins Tumor Drug Trial in China

MT Newswires Live11-03 20:15

CSPC Pharmaceutical Group (HKG:1093) officially began a phase I/II clinical trial of SYS6088 injection at the first center in China.

The drug is being tested for the treatment of advanced solid tumors, a Tuesday bourse filing showed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment